Note 12 - Grants and Collaboration Revenue

9 Months Ended

Sep. 30, 2020

Notes to Financial Statements

Government Grants and Contracts [Text Block]

12. Grant and Collaboration Revenue

We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the

three

-month and

nine

-month periods ended

September 30, 2020,

we recorded

$231,330

and

$1,186,844,

respectively, of revenues associated with these grants and contracts, as compared to

$214,765

and

$754,022,

respectively, for the comparable periods of

2019.

As of

September 30, 2020,

there was an aggregate of

$417,121

in approved grant funds available for use through

September 2021.

During the

three

-month and

nine

-month periods ended

September 30, 2020,

we recorded

$184,127

and

$385,193,

respectively, of revenues associated with research collaboration agreements with

third

parties, as compared to

$118,444

and

$153,360,

respectively, for the comparable periods of

2019.